Management of cardiovascular risk in patients with multiple myeloma

Blood Cancer Journal
Chris PlummerMaría-Victoria Mateos

Abstract

Multiple myeloma (MM) is a plasma cell malignancy that accounts for 10% of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. MM can cause cardiac comorbidities such as cardiomyopathy and heart failure caused by cardiac amyloidosis and/or anemia. Some of the treatments used in MM can also affect cardiovascular health. Advances in pharmacotherapy for MM, such as the introduction of immunomodulators, proteasome inhibitors, histone deacetylase inhibitors, and monoclonal antibodies, have dramatically improved progression-free survival and life expectancy, but new agent classes are associated with adverse events that were not previously observed on a regular basis, including cardiovascular events. However, with careful risk assessment, monitoring, and prophylactic therapy, many of these cardiovascular complications can be managed or treated successfully. Most routine cardiovascular surveillance is undertaken by the treating hemato-oncologist, but a multidisciplinary approach involving cardiologists may help to optimize patient outcomes. In this review, we survey the cardiac complications commonly r...Continue Reading

References

Sep 26, 2000·Molecular Genetics and Metabolism·M S HorensteinT J L'Ecuyer
Jul 10, 2002·Journal of the American College of Cardiology·Mark J SarnakAndrew S Levey
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Oct 27, 2005·Journal of Molecular Modeling·Neil J Harrison, Sarah C R Lummis
Dec 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarUNKNOWN Eastern Cooperative Oncology Group
Apr 26, 2006·Journal of Clinical Periodontology·D A C Van StrydonckG A Van der Weijden
May 23, 2006·Bone Marrow Transplantation·N J Bahlis, H M Lazarus
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Dec 21, 2007·Leukemia·A PalumboUNKNOWN International Myeloma Working Group
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Sep 9, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Jiahao LiuChang-seng Liang
Dec 1, 2009·Clinics in Geriatric Medicine·Ali Yazdanyar, Anne B Newman
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D BovelliUNKNOWN ESMO Guidelines Working Group
Sep 16, 2010·Current Hypertension Reports·Carrie Anna Geisberg, Douglas B Sawyer
May 4, 2011·Clinical Cardiology·Victor FelizMaya Guglin
Dec 20, 2011·Clinical Lymphoma, Myeloma & Leukemia·Antonio PalumboJesus San Miguel
Jul 14, 2012·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Sep 19, 2012·Circulation·C Cristina QuartaRodney H Falk
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CuriglianoUNKNOWN ESMO Guidelines Working Group
Jun 12, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Abhishek SinglaShaji K Kumar
Jun 22, 2013·Clinical Lymphoma, Myeloma & Leukemia·Jonathan L KaufmanPaul G Richardson
Feb 6, 2014·Haematologica·Shameem MahmoodAshutosh Wechalekar
Apr 10, 2014·Journal of Cellular and Molecular Medicine·Lenka KubiczkovaSabina Sevcikova
Oct 4, 2014·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A N BalamuruganF B Barton
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Mar 6, 2015·Frontiers in Oncology·Giampaolo TalamoJohn M Varlotto
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Oct 18, 2015·Nefrología : publicación oficial de la Sociedad Española Nefrologia·Claudia BentoMaurício Carvalho
Dec 24, 2015·Oncotarget·Susanne LubEls Van Valckenborgh

❮ Previous
Next ❯

Citations

Jul 19, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Florentina Porsch, Christoph J Binder
Dec 1, 2020·Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia·Gabriel Acácio de Moura, Paula Bruno Monteiro
Jan 4, 2021·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Leila S AraniAbass Alavi
Dec 17, 2020·Life·Valentina GiudiceCarmine Selleri
Feb 4, 2021·Clinical Lymphoma, Myeloma & Leukemia·Claudia BellofioreConcetta Conticello
Jul 6, 2021·JACC. Basic to Translational Science·Tanyaporn PattarabanjirdColeen McNamara
Sep 1, 2021·Biological Trace Element Research·Hai-Bing YangShang Mao
Oct 15, 2021·Frontiers in Cardiovascular Medicine·Jie WangYang Yan
Nov 6, 2021·Expert Review of Hematology·Massimiliano CamilliAntonella Lombardo
Dec 7, 2021·Frontiers in Cardiovascular Medicine·Yongxin LiJie Wang
Apr 14, 2021·Cardiovascular & Hematological Disorders Drug Targets·Azka LatifFaiz Anwer

❮ Previous
Next ❯

Software Mentioned

ENDEAVOR

Related Concepts

Related Feeds

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

© 2022 Meta ULC. All rights reserved